Welcome to our dedicated page for Zai Lab SEC filings (Ticker: ZLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zai Lab Limited (ZLAB) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures related to its American Depositary Shares listed on the Nasdaq Global Market. Zai Lab is a research-based, commercial-stage biopharmaceutical company based in China and the United States, focused on oncology, immunology, neuroscience, and infectious disease. Its SEC filings offer detailed information on financial performance, risk factors, capital structure, and key corporate agreements.
Through this page, users can review Zai Lab’s current reports on Form 8-K, which have covered topics such as quarterly financial results and the entry into a material definitive agreement for a renminbi-denominated revolving credit facility to support working capital needs in mainland China. These filings also describe how certain information, including earnings press releases furnished as exhibits, is treated for purposes of the Securities Exchange Act of 1934.
In addition to 8-Ks, investors can use this page as a starting point to locate Zai Lab’s annual and other periodic reports filed with the SEC, which discuss its dual-engine strategy, commercial portfolio in China, and global research and development programs. For a biopharmaceutical company like Zai Lab, these documents are important for understanding product revenue sources, R&D investment, licensing arrangements for medicines such as VYVGART, NUZYRA, ZEJULA, AUGTYRO, and COBENFY, and the financial implications of its pipeline.
Stock Titan enhances the raw filing data with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly identify items such as new credit facilities, changes in operations, or significant clinical and commercial milestones referenced in the filings. Real-time updates from EDGAR, combined with organized access to forms including 8-K and other SEC documents, allow users to monitor ZLAB’s regulatory reporting and corporate actions efficiently.
Zai Lab Ltd officer Joshua L. Smiley reported an automatic tax-related sale of company stock. On April 6, 2026, he sold 3,017 American Depositary Shares (ADSs) at $20.448 per ADS to cover taxes due upon vesting of Restricted Share Units. Each ADS represents ten Ordinary Shares of Zai Lab. After this tax-cover transaction, Smiley directly held 117,602 ADSs, indicating he retained a substantial equity position in the company.
Zai Lab Ltd Chief Legal Officer Edmondson Frazor Titus III reported an automatic sale of 1,224 American Depositary Shares (ADSs) of Zai Lab Ltd to cover taxes upon vesting of Restricted Share Units. The ADSs were sold at an average price of $20.448 per ADS on April 6, 2026.
Each ADS represents ten Ordinary Shares of Zai Lab Ltd. Following this tax-related sale, Edmondson Frazor Titus III directly holds 23,366 ADSs. The transaction reflects a routine disposition tied to equity compensation rather than a discretionary open-market trade.
Zai Lab Ltd Chairperson and CEO Ying Du reported an open-market sale of 2,653 American Depositary Shares (ADSs) of the company at a price of $20.448 per ADS. A filing footnote explains these ADSs were sold automatically to cover taxes upon vesting of Restricted Share Units.
After this tax-related sale, Ying Du directly holds 1,122,626 ADSs. Each ADS represents ten ordinary shares of Zai Lab, and the ADSs and ordinary shares are fully fungible.
Zai Lab Ltd Chief Financial Officer Yajing Chen reported an open-market sale of 853 American Depositary Shares (ADSs) of Zai Lab on April 6, 2026 at an average price of $20.448 per ADS. Each ADS represents ten ordinary shares, and the company states its ADSs and ordinary shares are fully fungible, though this report is presented in ADS terms.
According to the disclosure, these ADSs were sold automatically to cover taxes triggered by the vesting of Restricted Share Units, indicating a tax-withholding related transaction rather than a discretionary portfolio decision. After this sale, Chen directly holds 31,705 ADSs, showing that the transaction affects only a small portion of her reported direct holdings.
Zai Lab Ltd officer Rafael Amado reported an open-market sale of 2,739 American Depositary Shares (ADSs) at $20.448 per ADS. Each ADS represents ten ordinary shares. After the transaction, he directly holds 57,022 ADSs.
According to the filing, these ADSs were sold automatically to cover taxes due upon the vesting of Restricted Share Units, indicating the sale was driven by tax obligations rather than a discretionary portfolio decision.
Zai Lab Limited filed a Schedule 13G reporting beneficial ownership of 57,435,330 ordinary shares, held via 5,743,533 ADSs (each ADS = ten ordinary shares). The stake represents 5.2% of shares outstanding based on 1,106,407,390 ordinary shares outstanding as of Feb 20, 2026. The holdings are reported by RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., and related individuals; voting and dispositive powers are described as shared holdings and certain disclaimers of beneficial ownership appear in the filing.
ZLAB reported proposed sales of American Depositary Shares via a Form 144 notice indicating insider dispositions. The filing lists a restricted stock vesting issuance of 3,017 ADS on 04/02/2026 and two reported past sales by Joshua L. Smiley totaling 11,580 ADS across 03/13/2026 and 04/02/2026.
ZLAB affiliate filed a Form 144 reporting proposed and recent sales of American Depositary Shares. The filing lists restricted stock vesting on 04/02/2026 and multiple dispositions by Ying Du in March–April 2026, including several 50,000-share sales and smaller transactions.
ZLAB reported a Form 144 notice listing proposed or recent sales of American Depositary Shares by Frazor T. Edmondson. The filing lists three transactions: 15,569 shares for $296,745.14 on 03/05/2026; 1,281 shares for $23,862.72 on 03/13/2026; and 4,194 shares for $85,516.08 on 04/02/2026
The filing also notes restricted stock vesting of American Depositary Shares on 04/02/2026 reported as compensation. The notice identifies Fidelity Brokerage Services LLC and lists NASDAQ as the exchange.
The filing is a Form 144 notice related to American Depositary Shares for ZLAB, dated 04/06/2026. It lists restricted stock vesting and multiple reported sales by Rafael Amado: 10,000 ADS on 03/03/2026 for $173,800, 2,957 ADS on 03/13/2026 for $55,083.59, and 9,910 ADS on 04/02/2026 for $202,065.89. The notice records broker and exchange information.